Celator and LLS form partnership
Through the partnership, The Leukemia & Lymphoma Society (LLS) will provide $3.7 million to support Celator’s Phase IIb multicenter, randomized, open-label trial of CPX-351 versus intensive salvage therapy
Akeso has received approval from China’s National Medical Products Administration (NMPA) for gumokimab (AK111), an anti-Interleukin-17 (IL-17) monoclonal antibody, to treat adults with moderate-to-severe plaque psoriasis.